<?xml version="1.0" encoding="UTF-8"?>
<p id="p0085">To minimize disruptions to ongoing trials, NCI has worked with FDA’s and NCI’s clinical trials networks to enable greater flexibility in trial operations. A few of the many adaptations that have been made to enable trials to continue include the following:
 <list list-type="simple" id="ulist0010">
  <list-item id="u0010">
   <label>•</label>
   <p id="p0090">Allowing patients’ local healthcare providers to conduct some study activities that typically require in-person visits to the trial site, such as testing and assessment, under the guidance of the trial investigators.</p>
  </list-item>
  <list-item id="u0015">
   <label>•</label>
   <p id="p0095">Shipping orally administered investigational drugs directly to patients or their local healthcare providers.</p>
  </list-item>
  <list-item id="u0020">
   <label>•</label>
   <p id="p0100">Obtaining informed consent remotely, based on guidance from the central institutional review board.</p>
  </list-item>
 </list>
</p>
